(AOF) – Walgreens Boots Alliance’s revenue in the first quarter of its fiscal 2024 increased 10% from the previous quarter to $36.7 billion, an increase of 8.7% at rate constant exchange rate. It reflects sales growth in the U.S. and international retail pharmacy sectors, as well as revenue contributions from the U.S. healthcare sector.
On the other hand, over this period, the American pharmacy chain still posted an operating loss of $39 million. It was reduced compared to the previous quarter: 6.2 billion dollars.
Over this quarter, adjusted earnings per share decreased by 43.1% to $0.66. However, the group maintains its adjusted EPS forecast for fiscal 2024 of $3.20 to $3.50.
AOF – LEARN MORE
Find out more about the “mass distribution” sector
Two major challenges for the sector
The turnover of distribution brands increased by 6.6% in the third quarter of 2022 according to the IRI panelist. Such a performance had not been recorded since the confinements of 2020. However, since the end of September, volumes have declined following the increase in prices. The results of French players, rather spared until now, should therefore suffer. Moreover, in the United States, Walmart and Target have issued warnings about their results.
Another challenge: logistical disorganization. According to NielsenIQ data, the out-of-stock rate increased further on the shelves to reach 5.8% at the end of October. This represents a shortfall of 3.5 billion euros since the start of the year. According to Système U, these disorders have never been observed for more than fifty years. The reasons are multiple: both climatic, geopolitical, logistical, inflationary, and also linked to the behavior of consumers, who stock certain items. On the other hand, the strike in the refineries seems to have had little impact because the brands managed to organize themselves.
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.